Abliva AB (publ) (NEVPF)

Abliva AB (publ) (NEVPF) Healthcare & Pipeline Overview

Abliva AB (publ) is a biotechnology firm specializing in the development of treatments for primary mitochondrial diseases, with a focus on advancing its clinical-stage drug candidates, KL1333 and NV354, through clinical trials and strategic collaborations, positioning it within the niche market of mitochondrial disease therapeutics.

What Is the Investment Thesis for NEVPF?

Abliva AB presents a focused investment opportunity within the niche market of primary mitochondrial disease therapeutics. The company's lead drug candidate, KL1333, in Phase 2/3 trials, represents a near-term value driver. Successful trial outcomes and subsequent regulatory approval could significantly increase the company's market capitalization. The development of NV354 for Complex I deficiency further diversifies the pipeline and addresses a specific subset of mitochondrial diseases. Key risks include clinical trial failures, regulatory hurdles, and the need for additional funding. The company's small market capitalization ($0.05B) and negative P/E ratio (-14.90) reflect its developmental stage and inherent risks. However, positive clinical data and strategic partnerships could drive substantial long-term value.

Based on FMP financials and quantitative analysis

NEVPF Key Highlights

• KL1333 is currently in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases, representing a significant milestone in the company's development.
• NV354 is in preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency, expanding Abliva's pipeline.
• Abliva has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments, enhancing its research and development capabilities.
• The company's focus on primary mitochondrial diseases addresses a significant unmet medical need in a growing market.
• Abliva's market capitalization is $0.05B with a negative P/E ratio of -14.90, reflecting its developmental stage and growth potential.

Who Are NEVPF's Competitors?

NEVPF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NEVPF's Key Strengths?

• Focus on a niche market with high unmet medical need.
• Lead drug candidate in Phase 2/3 clinical trials.
• Strong collaboration network with research institutions.
• Proprietary drug development platform.

What Are NEVPF's Weaknesses?

• Limited financial resources and small market capitalization.
• Dependence on clinical trial outcomes and regulatory approvals.
• Limited commercial infrastructure.
• High risk of clinical trial failure.

What Could Drive NEVPF Stock Higher?

• Results from Phase 2/3 clinical trials for KL1333.
• Initiation of clinical trials for NV354.
• Potential for new collaboration agreements with pharmaceutical companies.
• Progress in securing orphan drug designation for its therapies.

What Are the Key Risks for NEVPF?

• Financial-distress signal — its Altman Z-Score of 0.16 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for KL1333 or NV354.
• Regulatory hurdles and delays in drug approval.
• Need for additional funding and potential dilution of shareholders.
• Competition from other companies developing mitochondrial disease therapies.

What Are the Growth Opportunities for NEVPF?

• Growth opportunity 1: Successful completion of Phase 2/3 clinical trials for KL1333 represents a major growth catalyst. Positive trial results could lead to regulatory approval and commercialization, opening up a significant market opportunity for the treatment of primary mitochondrial diseases. The timeline for potential approval is estimated within the next 2-3 years, contingent on trial outcomes and regulatory review. This success would establish Abliva as a leader in the mitochondrial disease therapeutics market.
• Growth opportunity 2: Advancement of NV354 into clinical trials for Complex I deficiency offers another growth avenue. Complex I deficiency is a common form of mitochondrial disease, and a successful therapy could address a substantial patient population. The timeline for clinical trials is estimated within the next 1-2 years, with potential for commercialization in the longer term. This would diversify Abliva's product pipeline and revenue streams.
• Growth opportunity 3: Expansion of collaboration agreements with pharmaceutical companies and research institutions can accelerate the development of new therapies and expand Abliva's scientific knowledge. Strategic partnerships can provide access to new technologies, funding, and expertise, enhancing the company's competitive position. The timeline for new partnerships is ongoing, with potential for announcements in the near future.
• Growth opportunity 4: Exploring new indications for existing drug candidates, such as KL1333, can expand the market opportunity and extend the product lifecycle. Mitochondrial dysfunction is implicated in various diseases, and targeting these indications could unlock new revenue streams. The timeline for exploring new indications is ongoing, with potential for clinical trials in the coming years.
• Growth opportunity 5: Securing orphan drug designation for its lead drug candidates can provide regulatory and commercial advantages, including market exclusivity and tax incentives. Orphan drug designation is granted to therapies for rare diseases, and it can significantly enhance the attractiveness of a drug candidate. The timeline for securing orphan drug designation is ongoing, with potential for approval in the near future.

What Opportunities Does NEVPF Have?

• Successful commercialization of KL1333.
• Expansion of product pipeline through new drug candidates.
• Strategic partnerships with pharmaceutical companies.
• Securing orphan drug designation for its therapies.

What Threats Does NEVPF Face?

• Competition from other companies developing mitochondrial disease therapies.
• Regulatory hurdles and delays in drug approval.
• Clinical trial failures and setbacks.
• Need for additional funding and potential dilution of shareholders.

What Are NEVPF's Competitive Advantages?

• Specialized expertise in mitochondrial disease biology and drug development.
• Proprietary drug candidates targeting specific mitochondrial dysfunctions.
• Strong relationships with key opinion leaders and research institutions.
• Patent protection for its drug candidates and technologies.

What Does NEVPF Do?

Abliva AB (publ), formerly known as NeuroVive Pharmaceutical AB, is a Swedish biotechnology company dedicated to developing innovative therapies for primary mitochondrial diseases. Incorporated in 2000 and headquartered in Lund, Sweden, Abliva's mission is to address the unmet medical needs of patients suffering from these rare and often debilitating conditions. The company's lead product candidate, KL1333, is currently in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases. KL1333 represents a significant advancement in the potential treatment of these diseases. In addition to KL1333, Abliva is also developing NV354, which is in preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency. Furthermore, Abliva has a pre-clinical project, targeting energy regulation and mitochondrial function. Abliva also has NeuroSTAT, which is in Phase 1b/2a clinical study for traumatic brain injury. Abliva collaborates with various organizations, including Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments, to advance its research and development efforts. These collaborations are crucial for expanding Abliva's scientific knowledge and accelerating the development of new therapies. The company's focus on mitochondrial diseases positions it within a specialized and growing area of the biotechnology industry.

What Products and Services Does NEVPF Offer?

• Develop medicines for the treatment of primary mitochondrial diseases.
• Conduct clinical trials for drug candidates targeting mitochondrial dysfunction.
• Collaborate with research institutions and pharmaceutical companies to advance drug development.
• Focus on addressing unmet medical needs in rare genetic disorders.
• Develop KL1333 for chronic treatment of primary mitochondrial diseases.
• Develop NV354 for treatment of primary mitochondrial diseases with Complex I deficiency.
• Conduct Phase 1b/2a clinical study for NeuroSTAT in traumatic brain injury.

How Does NEVPF Make Money?

• Develop and commercialize pharmaceutical products for primary mitochondrial diseases.
• Generate revenue through sales of approved therapies.
• Collaborate with partners for research, development, and commercialization.
• Seek funding through grants, venture capital, and public offerings.

What Industry Does NEVPF Operate In?

Abliva operates within the biotechnology industry, specifically targeting the niche market of primary mitochondrial diseases. This market is characterized by a high unmet medical need and a growing awareness of mitochondrial dysfunction in various diseases. The competitive landscape includes companies developing therapies for rare genetic disorders and metabolic diseases. Abliva's focus on mitochondrial diseases positions it within a specialized segment of the broader biotechnology market, with potential for significant growth as new therapies are developed and approved.

Who Are NEVPF's Key Customers?

• Patients suffering from primary mitochondrial diseases.
• Healthcare providers treating patients with mitochondrial disorders.
• Pharmaceutical companies seeking to collaborate on drug development.
• Research institutions involved in mitochondrial disease research.

FY2026 estForward Outlook

Wall Street analysts project Abliva AB (publ) revenue of about $197K for fiscal 2026, with EPS near $-0.09.

Quarterly Financial Performance: Abliva AB (publ)

Revenue for Abliva AB (publ) came in at $0 during Q4 2024. The company recorded a net loss of $26.5M, with diluted EPS of $-0.02. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, NEVPF averaged $-0.02 in diluted EPS.

NEVPF Valuation & Market Position

With a $45.13M market cap, Abliva AB (publ) sits in the micro-cap segment of the market. Relative to its peer group, NEVPF's quantitative score of 61/100 is above the peer average of 46/100.

Key Financial Metrics

Its free cash flow yield is -14.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.13 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -20.4%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 2/9Financial Health

Abliva AB (publ)'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 0.16 places it in the distress zone, a signal of elevated financial risk.

Company Profile

Abliva AB (publ) operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Lund, SE. The company is led by CEO Ellen K. Donnelly. NEVPF has traded publicly since 2014.

NEVPF Financials

NEVPF Latest News

NEVPF Analyst Consensus

NEVPF MoonshotScore

What Investors Ask About Abliva AB (publ) (NEVPF) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources